StockNews.com Initiates Coverage on Marinus Pharmaceuticals (NASDAQ:MRNS)

StockNews.com assumed coverage on shares of Marinus Pharmaceuticals (NASDAQ:MRNS) in a report published on Friday. The firm issued a hold rating on the biopharmaceutical company’s stock.

Other research analysts have also recently issued research reports about the stock. Jefferies Financial Group reaffirmed a “hold” rating and issued a $0.50 price objective (down previously from $5.00) on shares of Marinus Pharmaceuticals in a report on Friday, October 25th. Oppenheimer upgraded Marinus Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $6.00 price target for the company in a research note on Monday, September 23rd. JMP Securities reiterated a “market perform” rating on shares of Marinus Pharmaceuticals in a research report on Thursday, October 24th. HC Wainwright reissued a “neutral” rating and issued a $2.00 price objective on shares of Marinus Pharmaceuticals in a report on Thursday, November 14th. Finally, TD Cowen reaffirmed a “hold” rating on shares of Marinus Pharmaceuticals in a research note on Friday, October 25th. Nine research analysts have rated the stock with a hold rating, two have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $4.79.

Marinus Pharmaceuticals Price Performance

Shares of NASDAQ MRNS opened at $0.23 on Friday. The stock has a market capitalization of $12.69 million, a price-to-earnings ratio of -0.09 and a beta of 1.25. The firm’s 50 day simple moving average is $0.54 and its 200-day simple moving average is $1.12. Marinus Pharmaceuticals has a 12 month low of $0.23 and a 12 month high of $11.26.

Institutional Investors Weigh In On Marinus Pharmaceuticals

A number of large investors have recently modified their holdings of MRNS. Franklin Resources Inc. boosted its position in Marinus Pharmaceuticals by 34.9% during the third quarter. Franklin Resources Inc. now owns 4,713,014 shares of the biopharmaceutical company’s stock worth $8,483,000 after acquiring an additional 1,219,871 shares during the last quarter. World Investment Advisors LLC purchased a new position in Marinus Pharmaceuticals in the 3rd quarter worth approximately $104,000. Jacobs Levy Equity Management Inc. boosted its holdings in shares of Marinus Pharmaceuticals by 39.5% during the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 414,269 shares of the biopharmaceutical company’s stock worth $729,000 after purchasing an additional 117,255 shares during the last quarter. Suvretta Capital Management LLC grew its position in shares of Marinus Pharmaceuticals by 32.8% in the third quarter. Suvretta Capital Management LLC now owns 5,073,913 shares of the biopharmaceutical company’s stock valued at $8,930,000 after purchasing an additional 1,253,901 shares in the last quarter. Finally, GSA Capital Partners LLP increased its holdings in shares of Marinus Pharmaceuticals by 409.4% in the third quarter. GSA Capital Partners LLP now owns 1,016,634 shares of the biopharmaceutical company’s stock valued at $1,789,000 after purchasing an additional 817,050 shares during the last quarter. Hedge funds and other institutional investors own 98.80% of the company’s stock.

About Marinus Pharmaceuticals

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.